The pharma sector is likely to maintain steady earnings. Most brokerages flag US business recovery as the key swing factor ...

Sun Pharmaceutical Industries Ltd. closed 10.67% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Sun Pharma declined 0.93 per cent to Rs 1,689.35. About10 per cent of the Sun Pharma's US specialty revenues is formulated in ...

Pharma Stocks; The Indian pharma market experienced a robust growth of 9.3% year-on-year in March 2025, with key players like ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharmaceutical Industries Ltd. closed 13.65% short of its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

Indian equities soar to record highs, erasing year-to-date losses in best week in four years, led by financial sector.

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...

Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock. Keep track of Sun Pharma with the latest details, including: Last ...

Sun Pharma has received a favourable ruling from the US Court of Appeals for the Federal Circuit, which has vacated the preliminary injunction effective immediately, paving way for the launch of ...